1. K.
Park and D.Z. D'Argenio. Stochastic control
of pharmacodynamic processes with application
to ergotamine. In D.Z. D'Argenio (ed.),
Advanced Methods of Pharmacokinetic and
Pharmacodynamic Systems Analysis, Vol. 2,
Plenum Press, New York, pp. 189-204, 1995
2. D.Z. D'Argenio and K. Park. Uncertain
pharmacokinetic/ pharmacodynamic systems:
Design, estimation and control. Control
Eng. Practice 5:1707-1716, 1997
3. K. Park, D. Verotta, T.F. Blaschke and
L.B. Sheiner. A semiparametric method for
describing noisy population pharmacokinetic
data. J. Pharmacokin. Biopharm. 25: 615-642,
1997
4. G.F. Vanhove, H. Kastrissios, J.M. Gries,
D. Verotta, K. Park, A.C. Collier, K Squires,
L.B. Sheiner, and T.F. Blaschke. Pharmacokinetics
of saquinavir, zidovudine, and zalcitabine
in combination therapy. Antimicrob. Agents
Chemother 41:2428-32, 1997
5. K. Park, D. Verotta, S.K. Gupta and
L.B. Sheiner. Passive versus electrotransport-facilitated
transdermal absorption of ketorolac. Clin.
Pharmacol. Ther. 63:303-315, 1998
6. K. Park, D. Verotta, S.K. Gupta and
L.B. Sheiner. Use of a pharmacokinetic/pharmacodynamic
model to design an optimal dose input profile.
J. Pharmacokin. Biopharm. 26: 471-492, 1998
7. M.E. Krecic-Shepard, K. Park, C. Barnas,
J. Slimko, D.R. Kerwin and J.B. Schwartz.
Race and sex influence clearance of nifedipine:
Results of a population study. Clin. Pharmacol.
Ther. 68: 130-42, 2000
8. K. Park and D.Z. D'Argenio. Control
of Uncertain Pharmacodynamic Systems. In
D.Z. D'Argenio (ed.), Advanced Methods of
Pharmacokinetic and Pharmacodynamic Systems
Analysis, Vol. 3, Kluwer Academic Publishers,
Norwell, MA, pp. 275-293, 2004
9. K. Park, E. J. Hur, K. W. Han, H. Y.
Kil, T. H. Han, Bispectral Index Does Not
Correlate With Observer Assessment of Alertness
and Sedation Scores During 0.5% Bupivacaine
Epidural Anesthesia with Nitrous Oxide Sedation,
Anesth Analg 103(2):385-9, 2006
10. K. Park, Y. S. Kim, K. I. Kwon, M.
S. Park, Y. J. Lee, K. H. Kim, A Randomized,
Open-Label, Two-Period, Crossover Bioavailability
Study of Two Oral Formulations of Tacrolimus
in Healthy Korean Adults. Clin Ther 29(1):
154-162, 2007
11. J. H. Choi, Y. J. Lee, S. B. Jang,
J. E. Lee, K. H. Kim, K. Park. Influence
of the CYP3A5 and MDR1 genetic polymorphisms
on the pharmacokinetics of tacrolimus in
healthy Korean subjects. Br J Clin Pharmacol
64(2): 185-191, 2007
12. J. H. Choi, M. G. Lee, J. Y. Cho, J.
E. Lee, K. H. Kim, K. Park, Influence of
OATP1B1 genotype on the pharmacokinetics
of rosuvastatin in Koreans. Clin. Pharmacol.
Ther. 83(2): 251-257, 2008
13. J. H. Sohn, H. J. Choi, J. T. Lee,
J. D. Lee, J. H. Kim, Y. M. Moon, K. Park,
K. B. Park, E. Kim, N. C. Yoo, Phase II
study of transarterial holmium-166-chitosan
complex in patients with a single, large
hepatocellular carcinoma. Oncology 76(1):
1-9, 2009
14. Y. S. Yim, J.
S. Choi, S. B. Jang, G. T. Kim, K. Park,
C. H. Kim, J. Cheon, D. G. Kim, Pharmacokinetic
properties and tissue storage of FITC conjugated
SA-MnMEIO nanoparticles in mice. Current
Applied Physics 9: e304-e307 (June 2009)
15. H. C. Kim, Y. J. Cho, C. W. Ahn, K.
Park, J. C. Kim, J. S. Nam, Y. S. Im, J.
E. Lee,
S. C. Lee and H. K. Lee, Nerve growth factor
and expression of its receptors in patients
with diabetic neuropathy. Diabetic Medicine
26: 1228-34 (December 2009)
16. S. B. Jang, Y. J. Lee, L. A. Lim, K.
M. Park, B. J. Kwon, J. S. Woo, Y. I. Kim,
M. S. Park, K. H. Kim, K. Park, Pharmacokinetic
Comparison of Controlled-Release and Immediate-Release
Oral Formulations of Simvastatin in Healthy
Korean Subjects: A Randomized, Open-label,
Parallel-Group, Single- and Multiple-Dose
Study. Clin Ther 32(1): 206-216 (January
2010).
17. D. W. Han, K. Park S. B. Jang, S. E.
Kern, Modeling the Effect of Sevoflurane
on corrected QT Prolongation: A Pharmacodynamic
Analysis. Anesthesiology 113(4): 806-11
(October 2010)
18. S. J. Shin, H. C. Jeung, J. B. Ahn,
S. Y. Rha, J. K. Roh, K. Park, D. H. Kim,
C. Kim, H. C. Chung, A phase I pharmacokinetic
and pharmacodynamic study of CKD-732, an
antiangiogenic agent, in patients with refractory
solid cancer. Invest New Drugs 28(5): 650-58
(2010)
19. J. Y. Chung, S. B. Jang, Y. J. Lee,
M. S. Park, K. Park, Effect of CYP2B6 genotype
on the pharmacokinetics of sibutramine and
active metabolites in healthy subjects.
J Clin Pharmacol 51(1): 53-59 (January 2011)
20. S. K. Cho, J. S. Yoon, M. G. Lee, D.
H. Lee, L. A. Lim, K. Park, M. S. Park,
J. Y. Chung, Rifampin enhances the glucose-lowering
effect of metformin and increases OCT1 mRNA
levels in healthy participants. Clin. Pharmacol.
Ther. 89(3): 416-20 (March 2011)
21. S. B. Jang, Y. J. Lee, M. S. Park,
Y. G. Song, J. H. Kim, H. K. Kim, B. S.
Ahn, K. Park, Population pharmacokinetics
of amikacin in Korean inpatients undergoing
TDM. Int J Clin Pharmacol Ther 49(6): 371-381
(June 2011)
22. D. Lee, L. A. Lim, S. B. Jang, Y. J.
Lee, J. Y. Chung, J. R. Choi, K. Kim, J.
W. Park, H. Yoon, J. Lee, M. S. Park, K.
Park, Pharmacokinetic Comparison of Sustained-
and Immediate-Release Oral Formulations
of Cilostazol in Healthy Korean Subjects:
A Randomized, Open-Label, 3-Part, Sequential,
2-Period, Crossover, Single-Dose, Food-Effect,
and Multiple-Dose Study. Clin Ther 33(12):
2038-2053 (December 2011).
23. S. J. Shin, J. B. Ahn, K. Park, Y.
J. Lee, Y. S. Hong, T. W. Kim, H. R. Kim,
S. Y. Rha, J. K. Roh, D. H. Kim, C. Kim,
H. C. Chung. A Phase Ib pharmacokinetic
study of the anti-angiogenic agent CKD-732
used in combination with capecitabine and
oxaliplatin (XELOX) in metastatic colorectal
cancer patients who progressed on irinotecan-based
chemotherapy. Invest New Drugs 30(2): 672-80
(April 2012).
24. S. K. Cho, E. S. Oh, K. Park, M. S.
Park, J. Y. Chung. The UGT1A3*2 polymorphism
affects atorvastatin lactonization and lipid-lowering
effect in healthy volunteers. Pharmacogenet
Genomics 22(8): 598-605 (August 2012).
25. E. S. Oh, S. H. Lee, M. S. Park, K.
Park, J. Y. Chung. Modeling of the LDL cholesterol-lowering
effect of atorvastatin in Korean dyslipidemic
patients and non-patient volunteers. Int
J Clin Pharmacol Ther 50(9): 647-56 (September
2012).
26. H. Roh, H. Son, D. Lee, K. J. Yeon,
H. S. Kim, K. Park. Pharmacokinetic Comparison
of an Orally Disintegrating Film Formulation
with a Film Coated Tablet Formulation of
Sildenafil in Healthy Korean Subjects: A
Randomized, Open-Label, 2-Period, Cross-Over,
and Single-Dose Study. Clin Ther 35(3):
205-214 (March 2013).
27. H. Son, H. Roh, D. Lee, H. Chang, J.
Kim, C. Yun, K. Park. Pharmacokinetics of
Rosuvastatin/Olmesartan Fixed-Dose Combination:
A Single-Dose, Randomized, Open-Label, 2-Period
Crossover Study in Healthy Korean Subjects.
Clin Ther 35(7): 915-922 (July 2013).
28. Y. Kim, M. Son, D. Lee, H. Roh, H.
Son, D. Chae, M. Y. Bahng, K. Park. Pharmacokinetic
Comparison of 2 Fixed-Dose Combination Tablets
of Amlodipine and Valsartan in Healthy Male
Korean Volunteers: A Randomized, Open-Label,
2-Period, Single-Dose, Crossover Study.
Clin Ther 35(7): 934-940 (July 2013).
29. H. Son, D. Lee, L. A. Lim, S. B. Jang,
H. Roh, K. Park. Development of a Pharmacokinetic
Interaction Model for Co-administration
of Simvastatin and Amlodipine. Drug Metab.
Pharmacokinet. (in press).
30. Son H, Lee DH, Lim LAY, Jang SB, Roh
HR, Park K: Development of a Pharmacokinetic
Interaction Model for Co-administration
of Simvastatin and Amlodipine. DRUG METABOLISM
AND PHARMACOKINETICS 29(2): 120-128, 2014
31. Son MJ, Kim Y, Lee DH, Roh HR, Son
H, Guk J, Jang SB, Nam SY, Park K: Pharmacokinetic
Interaction between Rosuvastatin and Telmisartan
in Healthy Korean Male Volunteers: A Randomized,
Open-label, Two-period, Crossover, Multiple-dose
Study. CLINICAL THERAPEUTICS 36(8): 1147-1158,
2014
32. Roh HR, Son H, Lee DH, Chang HC, Yun
C, Park K: Pharmacokinetic Interaction between
Rosuvastatin and Olmesartan: A Randomized,
Open-label, 3-period, Multiple-dose Crossover
Study in Healthy Korean Male Subjects. CLINICAL
THERAPEUTICS 36(8): 1159-1170, 2014
33. Lee DH, Roh HR, Son H, Jang SB, Lee
S, Nam SY, Park K: Pharmacokinetic Interaction
between Rosuvastatin and Metformin in Healthy
Korean Male Volunteers: A Randomized, Open-label,
3-period, Crossover, Multiple-dose Study.
CLINICAL THERAPEUTICS 36(8): 1171-1181,
2014
34.Lee D, Son H, Lim L, Park K: Population
pharmacokinetic analysis of diurnal and
seasonal variations of plasma concentrations
of cilostazol in healthy volunteers. THERAPEUTIC
DRUG MONITORING 36(6): 771-780, 2014
35. Chae DW, Son MJ, Kim Y, Son H, Jang
SB, Seo JM, Nam SY, Park K: Pharmacokinetics
of a telmisartan/rosuvastatin fixed-dose
combination: a single-dose, randomized,
open-label, 2-period crossover study in
healthy Korean subjects. INTERNATIONAL JOURNAL
OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
53(10): 883-889, 2015
36. S. Y. Kim, D. W. Chae, Y. M. Chun, K.
H. Jeong, K. Park and D. W. Han. Modelling
of the Effect of End-Tidal Carbon Dioxide
on Cerebral Oxygen Saturation in Beach Chair
Position under General Anaesthesia. Basic
& Clinical Pharmacology & Toxicology
119(1): 85-92 (July 2016)
37. M. Son, J. Guk, Y. Kim, D.W. Chae,
Y. Heo, D. Soh, K. Park. Pharmacokinetic
Interaction Between Rosuvastatin, Telmisartan,
and Amlodipine in Healthy Male Korean Subjects:
A Randomized, Open-label, Multiple-dose,
2-period Crossover Study. Clin Ther 38(8):
1845-1857 (August 2016).
38. D. W. Chae, H. Son, J. Guk, C. Park,
K. Park. Pharmacokinetics of a nanocrystal-containing
megestrol acetate formulation: A Single-Dose,
Randomized, Open-Label, 2-Part, 2-Period
Crossover Study in Healthy Korean Subjects.
Int J Clin Pharm Th 54(9): 698-704 (September
2016)
39. Y. A. Heo, N. Holford, Y. Kim, M. Son,
K. Park. Quantitative Model for the Blood
Pressure Lowering Interaction of Valsartan
and Amlodipine. British Journal of Clinical
Pharmacology 82 (6): 1557-1567 (December
2016)
40. K. Park. A Review of Modeling Approaches
to Predict Drug Response in Clinical Oncology.
Yonsei Medical Journal 58(1): 1-8 (January
2017)
41. J. Guk, H. Son, D. W. Chae, K. Park.
Quantitative assessment of food effect on
the pharmacokinetics of nano-crystallized
megestrol acetate. Basic & Clinical
Pharmacology & Toxicology 120(3): 270-277
(March 2017)
42. D. W. Chae, M. Son, Y. Kim, H. Son,
K. Park. Mechanistic Model for Blood Pressure
and Heart Rate Changes Produced by Telmisartan
in Human Beings. Basic & Clinical Pharmacology
& Toxicology 122(1): 139-148 (January
2018)
43. D. Chae, C. M. Nam, J. H. Kim, C. K.
Lee, S. S. Kim, H. S. Kim, M. Jung, J. H.
Cheong, H. C. Chung, S. Y. Rha, K. Park.
A Prediction Model of Tumor Progression
and Survival in HER2-Positive Metastatic
Gastric Cancer Patients Treated with Trastuzumab
and Chemotherapy. The AAPS Journal 20(4):72
(May 2018)
44. D. Chae, K. Park. An item response
theory based integrated model of headache,
nausea, photophobia, and phonophobia in
migraine patients. Journal of Pharmacokinetics
and Pharmacodynamics 45(5): 721-731 (October
2018)
45. J. Guk, D. Chae, H. Son, J. Yoo, J.
H. Heo, K. Park. Model-based assessment
of the benefits and risks of recombinant
tissue plasminogen activator treatment in
acute ischaemic stroke. British Journal
of Clinical Pharmacology 84 (11): 2586-2599
(November 2018)
46. Y. S. Jung, D. Chae, K. Park. Population
PK-PD Model of Pegylated Interferon Alfa-2a
in Healthy Korean Men. Journal of Pharmaceutical
Sciences 107 (12): 3171-3178 (December 2018)
|
